QuidelOrtho Overview
- Year Founded
-
1937

- Status
-
Public
- Employees
-
6,600

- Stock Symbol
-
QDEL

- Investments
-
13
- Share Price
-
$28.01
- (As of Friday Closing)
QuidelOrtho General Information
Description
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Contact Information
Website
www.quidelortho.comCorporate Office
- 9975 Summers Ridge Road
- San Diego, CA 92121
- United States
Corporate Office
- 9975 Summers Ridge Road
- San Diego, CA 92121
- United States
QuidelOrtho Timeline
QuidelOrtho Stock Performance
As of 20-Jun-2025, QuidelOrtho’s stock price is $28.01. Its current market cap is $1.9B with 67.6M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$28.01 | $28.33 | $23.77 - $49.45 | $1.9B | 67.6M | 1.48M | -$4.97 |
QuidelOrtho Financials Summary
As of 31-Mar-2025, QuidelOrtho has a trailing 12-month revenue of $2.76B.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 4,941,706 | 5,608,287 | 7,401,140 | 8,268,906 |
Revenue | 2,764,700 | 2,782,900 | 2,997,800 | 3,266,000 |
EBITDA | 286,200 | (1,492,400) | 601,500 | 1,092,700 |
Net Income | (358,700) | (2,052,000) | (10,100) | 548,700 |
Total Assets | 6,461,600 | 6,423,600 | 8,563,100 | 8,855,800 |
Total Debt | 2,694,200 | 2,681,400 | 2,614,100 | 2,849,100 |
QuidelOrtho Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
QuidelOrtho Comparisons
Industry
Financing
Details
QuidelOrtho Competitors (18)
One of QuidelOrtho’s 18 competitors is DiaSorin, a Formerly PE-Backed company based in Saluggia, Italy.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
DiaSorin | Formerly PE-Backed | Saluggia, Italy | ||||
Hologic | Formerly VC-backed | Marlborough, MA | ||||
Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
Revvity | Corporation | Waltham, MA | ||||
Great Basin Scientific | Formerly VC-backed | West Valley City, UT |
QuidelOrtho Patents
QuidelOrtho Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240133881-A1 | Devices and kits for detecting analytes of interest and methods of using the same | Pending | 20-Oct-2022 | ||
AU-2023289398-A1 | System for visualizing and supporting a contextual diagnostic decision for contagious diseases | Pending | 22-Jun-2022 | ||
EP-4544571-A1 | System for visualizing and supporting a contextual diagnostic decision for contagious diseases | Pending | 22-Jun-2022 | ||
EP-4515229-A1 | Biosensor testing system and methods of use | Pending | 29-Apr-2022 | ||
AU-2022343290-A1 | Agglutinating agents, devices and methods for whole blood assays | Pending | 10-Sep-2021 | G01N33/56966 |
QuidelOrtho Signals
QuidelOrtho Investments & Acquisitions (13)
QuidelOrtho’s most recent deal was a Corporate with LEX Diagnostics. The deal was made on 01-Dec-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
LEX Diagnostics | 01-Dec-2023 | Corporate | Diagnostic Equipment | ||
Developer and Manufacturer of Assays (QuidelOrtho / Shanghai Runda Medical Technology Company) | 18-Dec-2022 | Joint Venture | Diagnostic Equipment | ||
Ortho-Clinical Diagnostics | 27-May-2022 | Merger/Acquisition | Diagnostic Equipment | ||
JRNYS | 10-Sep-2021 | Later Stage VC | Outcome Management (Healthcare) | ||
Alere (facility San Diego) | 06-Oct-2017 | Corporate Asset Purchase | Buildings and Property |
QuidelOrtho ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
24.66 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile

Healthcare
Industry
of 564
Rank
Percentile

Medical Devices
Subindustry
of 196
Rank
Percentile

QuidelOrtho Exits (1)
QuidelOrtho’s most recent exit was on 12-Apr-2002 from CymaBay Therapeutics. The exit was categorized as with 5 buyers.
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
CymaBay Therapeutics | 12-Apr-2002 | Completed |
|
QuidelOrtho Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
QuidelOrtho (Transfusion Medicine Unit) | San Diego, CA |
QuidelOrtho FAQs
-
When was QuidelOrtho founded?
QuidelOrtho was founded in 1937.
-
Where is QuidelOrtho headquartered?
QuidelOrtho is headquartered in San Diego, CA.
-
What is the size of QuidelOrtho?
QuidelOrtho has 6,600 total employees.
-
What industry is QuidelOrtho in?
QuidelOrtho’s primary industry is Diagnostic Equipment.
-
Is QuidelOrtho a private or public company?
QuidelOrtho is a Public company.
-
What is QuidelOrtho’s stock symbol?
The ticker symbol for QuidelOrtho is QDEL.
-
What is the current stock price of QuidelOrtho?
As of 20-Jun-2025 the stock price of QuidelOrtho is $28.01.
-
What is the current market cap of QuidelOrtho?
The current market capitalization of QuidelOrtho is $1.9B.
-
What is QuidelOrtho’s current revenue?
The trailing twelve month revenue for QuidelOrtho is $2.76B.
-
Who are QuidelOrtho’s competitors?
DiaSorin, Hologic, Bio-Rad Laboratories, Revvity, and Great Basin Scientific are some of the 18 competitors of QuidelOrtho.
-
What is QuidelOrtho’s annual earnings per share (EPS)?
QuidelOrtho’s EPS for 12 months was -$4.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »